PATENT CLAIM ANALYSIS

Application Number: 15745230
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-10
Patent Classification: ["424", "178100"]

Abstract:
The present invention belongs to the field of tumor therapy and molecular immunology, and relates to a PDL-1 antibody, a pharmaceutical composition thereof and use thereof. In particular, the present invention relates to a PDL-1 monoclonal antibody or an antigen-binding fragment thereof, wherein the monoclonal antibody has a heavy chain variable region comprising CDRs as set forth in SEQ ID NOs: 15-17; and/or has a light chain variable region comprising CDRs as set forth in SEQ ID NOs: 18-20. The monoclonal antibody of the present invention can bind to PDL-1 specifically, and specifically remove immunosuppressive function of PDL-1 and activate T lymphocytes.

Claim (Index 17):
A Hybridoma cell strain LT005, deposited in China Center for Type Culture Collection (CCTCC) with an accession number of CCTCC No: C2015133.

Metadata:
- Claim Count in Document: 132.0
- Percentile: 86.0
- Lexical Diversity: 1.88333
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15500744', '15761262', '14603808', '13297783', '12738883']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7560738166565972
- 35 USC 102 Novelty (BERT): 0.5482205789937832
- Combined Prediction Score: 0.7352884928903158
- Mean Citation Score: 370.982902
- Max Citation Score: 441.19925
- Similarity Product: 247.08041702015697

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test